Fcgamma receptor IIA genotype and susceptibility to P. aeruginosa infection in patients with cystic fibrosis.
It has been suggested that genes other than CFTR could modulate the severity of lung disease in cystic fibrosis (CF). Neutrophil Fcgamma receptor II (FcgammaRII) is involved in host defense against microorganisms and in inflammatory response. We evaluated the association between genetic variability of this gene and both airway infection with Pseudomonas aeruginosa and severity of lung disease in patients with CF. We studied 167 Italian unrelated patients with CF and 50 control subjects. The distribution of FcgammaRIIA genotypes in CF patients was compared with that in control subjects and the different genotypes were related with the presence or absence of P. aeruginosa infection and markers of disease severity in CF patients. The distribution of FcgammaRIIA genotypes was not significantly different between CF patients and controls. We observed that in CF patients with the same CFTR genotype (DeltaF508/DeltaF508), those carrying the R allele of FcgammaRIIA had an increased risk of acquiring chronic P. aeruginosa infection (P=0.042, R.R.: 4.38; 95% CI: 1.17/22.4). Moreover, the frequency of R/R genotype in patients with chronic P. aeruginosa infection seems to be higher than that of control subjects and patients without chronic infection. The observation that CF patients carrying the R allele of FcgammaRIIA are at higher risk of acquiring chronic P. aeruginosa infection suggests that the FcgammaRII loci genetic variation is contributing to this infection susceptibility.
De Rose
Virginia
V
Respiratory Disease Division, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. virginia.derose@unito.it
Arduino
Carlo
C
Cappello
Nazario
N
Piana
Rita
R
Salmin
Paola
P
Bardessono
Marco
M
Goia
Manuela
M
Padoan
Rita
R
Bignamini
Elisabetta
E
Costantini
Diana
D
Pizzamiglio
Giovanna
G
Bennato
Veronica
V
Colombo
Carla
C
Giunta
Annamaria
A
Piazza
Alberto
A
D000293:Adolescent; D000328:Adult; D000483:Alleles; D016022:Case-Control Studies; D002648:Child; D003550:Cystic Fibrosis / Q000235:genetics* / Q000276:immunology / Q000382:microbiology*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D004198:Disease Susceptibility; D005260:Female; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000378:metabolism; D011552:Pseudomonas Infections / Q000235:genetics* / Q000276:immunology; D011550:Pseudomonas aeruginosa / Q000235:genetics / Q000276:immunology; D017452:Receptors, IgG / Q000235:genetics*
C505032:CFTR protein, human; C445323:FCGR2A protein, human; C499173:FCGR2B protein, human; D017452:Receptors, IgG; D019005:Cystic Fibrosis Transmembrane Conductance Regulator